Pediatrix Therapeutics, a pediatrics-focused therapeutic company founded by Eight Roads, F-Prime Capital, and Creacion Ventures, has completed a Series A funding round co-led by the three founding investors. The pediatric therapeutics platform aims to bring high quality, pediatric-friendly, and affordable therapeutics to children and families in China.

China’s pediatric drug market has been growing at a rapid pace, with a 11.4% CAGR for the period of 2017 to 2021. However, there remains significant clinical unmet needs including the lack of drugs labelled and formulated specifically for the pediatric population, particularly in the prescription market. Pediatrix Therapeutics sees the opportunity to bring high quality, clinically validated drugs from overseas, and build a dedicated pediatrics ecosystem to address the high clinical unmet needs in the country.

Rebecca Lin, Senior Partner of Eight Roads stated: “Eight Roads is more than a financial investor. We look to build businesses that make a meaningful impact on society. Investing in Pediatrix as a co-founder is a reflection of this continued commitment. With the vast network of resources by this exceptional group of investors, we believe Pediatrix is well positioned to bridge the clinical gap in China’s pediatric therapeutic market.”